Our lead drug candidate, ENA-001, is a patent-protected new chemical entity (NCE) beginning additional clinical trials during the fourth quarter of 2021. With its novel mechanism of action and demonstrated safety and efficacy, it holds the potential to dramatically improving the lives of those impacted by several life-threatening conditions, including drug overdose, postoperative respiratory depression, and apnea of prematurity. ENA-001 will offer new treatment options for physicians, emergency responders, and caregivers addressing respiratory depression in multiple settings.